AzTrials
AzTrials

Type 2 DiabetesGLP-1inT2DNCT01977833

Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes

A study testing High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet) in people with Type 2 Diabetes, run by Tel Aviv University at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients. Read more about this study

Who is it for?
Ages 30 to 70 years
Conditions the study is for
Type 2 Diabetes
What is being tested?
High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteIsrael
Study dates
Oct 2013to Jan 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Type 2 diabetes patients
  • HbA1C > 7%
  • Duration of diabetes: 0.5 to 10 years
  • Subjects ≥ 30 and ≤70 years of age
  • BMI: 22 to 35 kg/m2
  • Diet controlled diabetic. Only treatment with metformin will be allowed
Show all 14Show fewer
  • Normal liver and kidney function
  • Normal thyroid function
  • Acceptable health beside diabetes based on interview, medical history, physical examination, and laboratory tests
  • Stable physical activity pattern during the three months immediately preceding study
  • Usually wakes up between 06:00 and 07:00 and goes to sleep between 22:00 and 24:00.
  • No shift work within 5 years of the study
  • Did not cross time zones within 1 month of the study
  • Read and understood the informed consent form and signed it voluntarily

Who cannot join

  • Type 1 diabetes
  • Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease
  • Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
  • Pregnancy or lactation
  • Illicit drug abuse or alcoholism
  • Treatment with antidiabetic drugs, insulin or GLP-1 analogs
Show all 10Show fewer
  • Subjects taking anoretic drugs during the month immediately prior to study
  • Subjects on steroid treatment
  • Those with eating disorders
  • Subjects after bariatric surgery, will be excluded

Trial locations and contacts

1 site in 1 country.

Daniela Jakubowicz, MD contact

972508105552

daniela.jak@gmail.com

Israel1 site, 1 recruiting
  • Diabetes Unit E. Wolfson Medical center

    Holon, Tel Aviv, 58100

    Daniela Jakubowicz, MD, 972508105552, daniela.jak@gmail.com

    Julio Wainstein, MD, 97254522296, vainstein@wolfson.health.gov.il

    Recruiting

Other trials in Israel

About this study

Official title: Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes

Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.

To test this hypothesis and clarify whether glucose, insulin and GLP-1 postprandial responses are different in the morning vs. in the afternoon, the investigators will compare in T2D subjects in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ in meal timing distribution The investigators hypothesize that GLP-1 and insulin response after high calorie breakfast will be higher in comparison to GLP-1 and insulin response after identical meal at evening

Read the detailed description

The endogenous circadian (24-h) timing system, synchronized by light/dark cycle in the master circadian clock in the suprachiasmatic nuclei and by meal timing in the peripheral clock genes; plays a significant role in regulating sleep/wake and feeding behavior, body weight as well as glucose and lipid metabolism.

Circadian misalignment, involving sleep/wake and meal timing schedules 12 h out of phase from their habitual times resulted in elevated blood pressure and increased postprandial glucose and insulin levels. Animal models of circadian misalignment specially breakfast skipping are associated with alteration in the expression pattern of clock genes such as Clock, Bmal1, Cry1, and Per2 in the liver and fat cells. These changes resulted in a predisposition to obesity and type 2 diabetes (T2D). This may also explain why evening or night eating is often associated with weight gain and obesity.

Breakfast skipping has been consistently associated with increased, visceral adiposity, higher BMI and waist circumference, insulin resistance, dyslipidemia and with T2D despite having less total daily caloric intake.

A recent population-based studies have found that participants with an evening preferences (late chronotype) that involves breakfast skipping, have 2.5 times risk of developing T2D, even after adjustment for body mass index (BMI) (12).

Breakfast skipping and greater percentage of their daily caloric intake at dinner was associated with higher fasting plasma glucose levels, and poorer glycemic control compared with earlier chronotypes even after adjusting for BMI (11,20,21). Recently was documented that in T2D patients, breakfast skipping was associated was associated with a 10.8% increase in HbA1C of its original value, even after adjusting for age, sex, race, BMI, number of diabetes complications, insulin use, depressive symptoms, perceived sleep debt, and percentage of daily caloric intake at dinner. This significant difference in HbA1C levels between breakfast skippers and breakfast eaters in patients with T2D, highlights the potential impact of the meal timing on the course of the disease.

More recently the investigators documented that compared to a conventional diet, a high caloric intake in the breakfast and reduced dinner resulted in significant reduction of HbA1c in T2D individuals.

The existence of diurnal variation in glucose tolerance in healthy and in subjects with T2D has been suspected for decades, with reports showing that glucose tolerance decreases progressively throughout the day with insulin sensitivity reaching a nadir in the evening. The reduction of glucose tolerance in the evening, seems to be a results from a combination of reduced glucose utilization, decreased insulin sensitivity, and inappropriately low insulin secretion and action, which highlights the importance of meal timing in glucose metabolism.

It is known that insulin response to meal ingestion is more rapid in the morning than in the afternoon and specifically the early (30 or 45 min) insulin secretion after oral glucose or meal ingestion is significantly higher in the morning than in the evening. A possible explanation for the more rapid glucose clearance from the circulation in the morning is because the early insulin response is important for rapid reduction in hepatic glucose output after meal ingestion.

Recently was shown that the enhanced early (30-min) insulin secretion after morning meal vs. afternoon, was accompanied by a correspondingly faster incretin total GLP-1 and intact GLP-1 hormone response in the morning specially during the first 30 min after ingestion. The association was consistent and also supports the prediction that higher GLP-1 levels after morning meal would result in a higher potentiation of β-cell function.

This diurnal pattern of enhanced insulin and GLP-1 response after morning meal versus in the evening, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.

To test this hypothesis the investigators will compare in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ only in meal timing distribution

  1. High caloric breakfast, average lunch and reduced dinner (BTdiet) and
  2. High caloric dinner, similar lunch and reduced breakfast (DTdiet)
Conditions
Type 2 Diabetes
Being tested
High Calorie Breakfast (BTdiet), High Caloric Dinner (DTdiet)
Keywords
BTdiet, Dtdiet, High Calorie Breakfast diet (BTdiet), High Calorie Dinner diet (DTdiet)
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High Calorie Breakfast (BTdiet)Other

    High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner

  • High Caloric Dinner (DTdiet)Other

    High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast

Study groups in NCT01977833
Study groupRoleWhat they receive
High Calorie Breakfast (BTdiet)ExperimentalHigh Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
Receives: Other: High Calorie Breakfast (BTdiet)
High Calorie Dinner (DTdiet)Active comparatorHigh Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
Receives: Other: High Caloric Dinner (DTdiet)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test

    All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma GLP-1 levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured

    Measured: During 3 hours after breakfast, lunch and dinner meal challange

Secondary outcomes (1)
  1. Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge

    All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured

    Measured: Postprandial Plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Nov 2013 (estimated)
  2. Study startOct 2013
  3. Primary completionDec 2013 (estimated)
  4. Study completionJan 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01977833
Sponsor's protocol ID
0145-13-WOMC
Acronym
GLP-1inT2D
Status last verified
Oct 2013
First submitted
31 Oct 2013
Last updated
7 Nov 2013
Results posted
No
Data monitoring committee
No

Publications

  • Jakubowicz D, Wainstein J, Ahren B, Bar-Dayan Y, Landau Z, Rabinovitz HR, Froy O. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. Diabetologia. 2015 May;58(5):912-9. doi: 10.1007/s00125-015-3524-9. Epub 2015 Mar 1.

    PubMed 25724569

Questions about this trial

What is this clinical trial studying?

A study testing High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet) in people with Type 2 Diabetes, run by Tel Aviv University at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Daniela Jakubowicz, MD (972508105552, daniela.jak@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test (time frame: During 3 hours after breakfast, lunch and dinner meal challange). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01977833, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in